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Abstract 
Complications resulting from vascular disease such as atherosclerosis are a major health 
concern in the United States. Treatments to remove atherosclerotic plaques from occluded blood 
vessels often result in injury causing aberrant vascular smooth muscle cell (VSMC) proliferation 
leading to restenosis and vessel occlusion, rendering the procedure ineffective. Methods to 
prevent restenosis are limited due to the lack of understanding of the signaling pathways 
involved. The Notch signaling pathway is known to be important in VSMC development and 
likely contributes to vascular diseases, such as atherosclerosis and arteriosclerosis, and may be 
involved in the restenosis process. This study will define the actions of Notch signaling, and its 
interaction with two prominent signaling pathways, Platelet Derived Growth Factor (PDGF), 
which promotes proliferation and dedifferentiation and Transforming Growth Factor Beta 
(TGFß), which induces differentiation of VSMC. To investigate Notch signaling in vascular 
cells, human aortic smooth muscle cells were cultured and treated with pathway activators and 
inhibitors. RNA and protein was isolated from cultured cells and Western blots and quantitative 
polymerase chain reactions were used to measure the effects on smooth muscle differentiation 
markers. Results from this study indicate that PDGF in conjunction with Notch signaling 
promotes dedifferentiation and TGFß in conjunction with Notch activity promotes differentiation 
in VSMC.  Differentiation and dedifferentiation was reduced when Notch signaling was 
inhibited. The conclusions from this research study have deepened the understanding of Notch 
signaling in vascular smooth muscle cells, and can possibly lead to the development of novel 
drug therapies to prevent restenosis. 
 
 
Introduction 
            Complications resulting from atherosclerosis are one of the leading causes of death in the 
United States.
7 
  These complications include cardiovascular disease, myocardial infarction and 
stroke.  The primary function of mature vascular smooth muscle cells is to maintain vascular 
tone and regulate blood pressure.
2   
Defects in vascular smooth muscle cells is a contributing 
factor in cardiovascular diseases as well as atherosclerosis.   Normal quiescent and mature 
vascular smooth muscle cells are non-proliferative and fully differentiated; expressing genes 
required for their contractile function.
2
   A vascular smooth muscle cell in a proliferative state 
has proven to be a clinical issue in mature blood vessels. For instance, balloon angioplasty is a 
procedure used to remove atherosclerotic plaque from an occluded blood vessel.  In the process 
of removing the atherosclerotic plaque the vessel wall is injured, which can result in smooth 
muscle cell proliferation leading to restenosis and vessel occlusion, rendering the procedure 
ineffective. Restenosis is the reoccurrence of stenosis or narrowing in a blood vessel after it has 
been treated with apparent success.  Methods to prevent restenosis are limited due to the lack of 
understanding of the signaling pathway involved. 
The evolutionarily conserved, Notch signaling pathway, is known to be important in 
vascular smooth muscle cell development, proliferation, migration and the development of 
vascular diseases such as atherosclerosis and arteriosclerosis.
5
 Notch signaling receptors are also 
expressed throughout the lifespan of VSMC.  Mice depleted in Notch1, Notch2, and Notch3 all 
present with vascular defects. 
2  
 Despite its prominent role in vascular smooth muscle cell 
physiology, the pathway is not completely characterized. Furthermore, the role it plays in smooth 
muscle proliferation and restenosis is not clear.  Published literature presents conflicting data on 
whether Notch signaling causes differentiation or dedifferentiation in vascular smooth muscle 
cells, suggesting complexity and potential interaction with other mediators.  Currently, the Notch 
signaling pathway is believed to be activated when a transmembrane ligand interacts with the 
extracellular domain of Notch receptors.  This causes the receptor of an adjacent cell to change 
shape which exposes sites for cleavage of the receptors by the enzymes ADAM17 and γ-
secretase.  This cleavage results in liberation of the intercellular domain and translocation into 
the nucleus of the cell, where transcription of Notch genes are induced, (figure 1).
2
  One way to 
inhibit Notch signaling activity experimentally is by the addition of DAPT.  DAPT targets the  γ-
secretase enzyme preventing cleavage of the intracellular domain. 
 A study found strong expression of both Notch2 and Notch3 receptors in arteries derived 
from normal human lung biopsies while Notch1 was undectable.
2
  As a result, this study attempts 
to uncover differences in the actions of Notch signaling, specifically Notch3, and its interaction 
with prominent signaling pathways in vascular smooth muscle cells.  Two pathways were studied 
in conjunction with the Notch3 signaling pathway.  Platelet Derived Growth Factor (PDGF), 
which promotes proliferation and dedifferentiation and Transforming Growth Factor Beta 
(TGFß), which induces differentiation of vascular smooth muscle cells.
3, 7  
 PDGF has been found 
to play a role in proliferative vascular smooth muscle diseases.  PDGF is one of the primary 
agents that induce the synthetic phenotype of VSMC from the quiescent contractile phenotype, 
leading to the development of atherosclerosis.
3  
TGFß plays a critical role in the pathogenesis of 
cardiovascular diseases, and regulates differentiation of VSMC.  TGFß has been found to affect 
endothelial cells, monocytes, macrophages, platelets and other cells present in atherosclerotic 
and restenosis lesions.
7  
Exploring the relationship between growth factors and Notch signaling 
may give insight into the causation of the restenosis process.  
 Notch, TGFß, and PDGF all influence VSMC, suggesting that they might interact to 
promote unique phenotypes in VSMC.  Therefore, I proposed to ask how the Notch signaling 
pathway affects the ability of PDGF to promote dedifferentiation, and TGFß to induce 
differentiation of vascular smooth muscles cells.  I postulated that Notch signaling modulates the 
actions of PDGF and TGFß on vascular smooth muscle cells to alter their phenotype and 
function.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Notch Signaling Pathway. Notch signaling pathway is activated when the transmembrane ligand 
interacts with the extracellular domain of Notch receptors.  The receptor undergoes a conformational change which 
exposes sites for cleavage of the receptors ADAM17 and γ-secretase.  Cleavage results in liberation of the 
intercellular domain and translocation into the nucleus of the cell, where it induces transcription of Notch genes.  
DAPT experimental treatment can inhibit Notch signaling by targeting the γ-secretase enzyme and preventing 
cleavage of the intracellular domain. 
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Figure 2. Research Hypothesis Notch signaling may modulate the ability of PDGF to promote dedifferentiation, 
and TGFß to induce differentiation of vascular smooth muscle cells. The inhibition of Notch3, by DAPT will 
weaken the growth factors’ (PDGF and TGFß) ability to alter vascular smooth muscle cell phenotype and function. 
 
Materials and Methods 
Cells and Experimental Treatment 
 All of the experiments were conducted in human aortic smooth muscle cell cultures, and 
were grown in Dulbecco modified Eagle's minimal essential medium (DMEM media) and Fetal 
Bovine Serum (FBS), which is commonly used in cell culture.   To test the interaction between 
PDGF and Notch signaling, human aortic smooth muscle cells were serum starved by culturing 
in 0.2% Fetal Bovine Serum and DMEM media for two days then were treated with 10ng/µl of 
PDGF growth factor and 10ng/µl of the Notch inhibitor, DAPT.  DAPT targets the ɣ-secretase 
enzyme and inhibits the cleavage of the intracellular domain of the Notch Signaling Pathway,
 2 
(Figure 1). To uncover the interaction between TGFß and Notch, 10ng/µl of TGFß growth 
factors and DAPT was added to the human aortic smooth muscle cells. Treatments were added in 
24 hour and 48 hour time courses.  Cells that did not receive treatment served as the control.  
DAPT 
DAPT 
TGFβ TGFβ 
Dimethyl Sulfoxide (DMSO) was the vehicle for DAPT.  An equal amount of DMSO was added 
to cells that did not receive DAPT treatment. According to literature 10ng/µl is an acceptable 
dose for the growth factors and inhibitors. 
RNA Extraction (Trizol Method) 
 Treated cells were trypsinized by TRYPLE Express Trypsin and incubated at 37 
o
C for 5 
minutes.  5% FBS DMEM media was added to the cells to inhibit the action of trypsin.  Cells 
were centrifuged and the supernatant was removed. The resulting pellet was suspended in 
Ribizol reagent and incubated at 25 
o
C for 5 minutes.  Chloroform was added to the extract and 
incubated for 3 minutes. The extract was then centrifuged for 15 minutes at 4
 o
C.  The upper 
aqueous phase was removed and placed in tubes containing 2 µl of glycogen.  Isopropanol was 
added to the samples and incubated for 10 minutes and centrifuged for 10 minutes at 4 
o
C.  The 
resulting RNA pellet was washed with 75% ethanol and centrifuged for 5 minutes at 4
 o
C.  The 
RNA pellet was dried for 10 minutes at 37
 o
C and resuspended in nuclease free TE buffer. The 
RNA concentration was quantified using the NanoDrop Spectrophotometer. 
 
Reverse Transcription Polymerase Chain Reaction (RT Reaction) 
To 2 µl of RNA (25ng/µl) extracted by the Trizol method was added 18 µl of master mix 
(Invitrogen 5x Strand Buffer, 0.5µg/µl Random Primers, 10mM dNTP, 0.5 RNase Inhibitor, 0.5 
µl M-MLV Reverse Transcriptase and molecular grade water).  Samples were incubated at 37
o
C 
for 2 hours. After incubation, 70µl of nuclease free water was added to the samples resulting in 
cDNA. 
 
 
Quantitative Polymerase Chain Reactions 
 Relative gene expression was measured by primers for smooth muscle cell 
differentiation genes; calponin, Notch3, α-smooth muscle actin, smooth muscle myosin heavy 
chain, and SM22α.  Primer sets contained both forward and reverse primers at a concentration of 
50ng/µl.  Master Mix (5 µl of SYBR Green and 0.5 µl of primer set) was added to 4.5 µl of 
diluted cDNA.  Samples were run in duplicate, expression levels were normalized to GAPDH 
expression and compared by 2
ΔΔCT 
results. 
 
Protein Extraction 
Treated cells were typsinsized by TRYPLE Express Trypsin and incubated at 37 
o
C for 5 
minutes.  5% FBS DMEM media was added to the cells to inhibit the action of trypsin.  Cells 
were centrifuged and the supernatant was removed. Cells were resuspended in RIPA Buffer 
(phenylmethanesulfonyl fluoride (PMSF) 1x100, Protease Inhibitor 1x100) and chilled for 20 
minutes at 4
 o
C. The samples were centrifuged for 5 minutes at 4
 o
C and the supernatant 
containing protein was removed. Protein concentration was tested using the Bradford Assay. 
Samples were diluted with RIPA Buffer to contain a protein concentration of 20µg/µl.  To the 
samples were added 15 µl of 5x loading dye and samples were boiled for 5 minutes and were 
stored at -20 
o
C. 
 
Protein Immunoblot (Western Blot)  
 Protein extracted from cultured vascular smooth muscle cells was tested by Western 
blotting to identify protein expression as a result of the experimental treatment.  10% sodium 
dodecyl sulfate (SDS) polyacrylamide gels were prepared, samples were added and run in 10X 
Run Buffer (Glycine, Tris Buffer, 10% SDS and distilled water).  The gel was transferred to an 
Amershan Hybound ECL Nitrocellulose Membrane in Western Transfer Buffer (Glycine, Tris 
Buffer, 20% Methanol, and 0.5% SDS).  The membrane was stained with Ponceau stain (1% 
Ponceau in 5% Acetic Acid).  The membrane was blocked in milk (carnation 5% nonfat dry milk 
in TBS-T solution) for one hour, washed 3X 10 minutes in TBS-T solution, then blotted with 
primary antibodies, Notch3 rabbit antibody (1:1,000), α-smooth muscle actin rat antibody 
(1:2,000) and tubulin rat antibody (1:20,000) overnight.  Membranes were washed 3X 10 
minutes in TBS-T solution, and then blotted with rat and rabbit secondary antibody (1:5,000).   
The membranes were washed with TBS-T, added to a western blot cassette, where 
chemiluminescence reagents were added.  Tubulin served as a protein loading control for the 
Western Blot assay.   
 
Data Analysis 
 Results from the gPCR were normalized to GAPDH expression and compared in groups 
of four.  Results were averaged and displayed with standard deviations.  ANOVA was used to 
test for statistical significance using a p-value of 0.05. 
 
Results 
Platelet Derived Growth Factor (PDGF) induces reduction in vascular smooth muscle cell 
differentiation. 
 Results from qPCR of smooth muscle differentiation markers, calponin (CNN1) and α-
smooth muscle actin (SMA) in cells treated with PDGF, revealed a significant decrease in 
differentiation compared to the control (Figure 3). Western blotting confirmed a qualitative 
decrease in α-smooth muscle actin protein intensity in cells treated with PDGF compared to the 
control.  Smooth muscle differentiation markers, smooth muscle myosin heavy chain (SMMHC) 
and sm22α (SM22), did not reveal a significant difference in expression compared to the control 
in the 24 hour time course (Figure 3A).   
  
Low level of Notch Signaling in cultured vascular smooth muscle cells. 
 Cells treated with the Notch inhibitor DAPT alone did not produce a significant 
difference compared to the control in vascular smooth muscle cell differentiation genes, CNN1, 
SM22α, SMMHC, and SMA.  Quantitative Polymerase Chain Reaction results for Notch3 gene 
expression revealed no significant decrease in cells treated with DAPT alone (Figure 3A) in the 
PDGF experiments.  In the TGFß experiments, there was a significant difference in Notch gene 
expression in cells treated with DAPT (Figure 4A).   Western blotting revealed a qualitative 
decrease in Notch3 protein intensity in cells treated with DAPT compared to control in both the 
PDGF and TGFß experiments, (Figure 3B, 4B). 
 
Inhibition of Notch by DAPT and addition of PDGF resulted in greater reduction in vascular 
smooth muscle cell differentiation. 
 Cells treated with DAPT and PDGF showed a significant decrease in differentiation in α-
smooth muscle actin (SMA) gene expression as well as in Notch3, (Figure 3A).  In SMA gene 
expression, there was a significant decrease in differentiation in cells treated with PDGF and 
DAPT compared to the cells treated with PDGF alone.  In Notch3 gene expression, the only 
significant difference was seen in cells treated with both PDGF and DAPT.   
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Figure 3A. Relative expression of vascular smooth muscle cell differentiation markers: Calponin (CNN1), 
NOTCH3, α-Smooth Muscle Actin (SMA), Smooth muscle myosin heavy chain (SMMHC) and Sm22α (SM22).  
Control denoted as (-/-).  Combined PDGF and DAPT treatment denoted as (+/+).  Significance denoted by asterisks 
(*p-value<0.05, **p-value <0.01, ***p-value <0.001, **** p-value<0.00001) and standard deviation denoted by 
figure bars. (n=5). 48 hour time course found in supplemental data. B. Western blot data for Notch3 and SMA.  
Tubulin served as a loading control. 
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Table 1. PDGF 24 hour time course statistics. Significant difference (p-value<0.05) denoted with an asterisk 
 
 
 
 
 
 
 
 
 
 
 
Gene treatment 2ΔΔCT Mean 
Difference 
Standard 
Deviation 
P-Value 
CNN1 PDGF/- 0.2261 0.08103 0.0004 * 
CNN1 -/DAPT 0.9489 0.6069 0.9525 
CNN1 +/+ 0.2338 0.09684 0.0008 * 
SMA 
SMA 
SMA 
PDGF/- 
-/DAPT  
+/+ 
0.3373 
0.9564 
0.2643 
0.07728 
0.3934 
0.05684 
0.0001 * 
0.8786 
<0.0001 * 
Notch3 PDGF/- 0.8257 0.4039 0.8340 
Notch3 -/DAPT 0.7705 0.4341 0.6815 
Notch3 +/+ 0.5369 0.2634 0.0064 * 
SMMHC PDGF/- 1.525 1.981 >0.9999 
SMMHC -/DAPT 6.991 10.86 0.4387 
SMMHC +/+ 2.489 3.209 0.8255 
SM22 
SM22 
SM22 
PDGF/- 
-/DAPT 
+/+ 
0.8720 
0.6194 
0.7110 
0.5231 
0.1392 
0.1845 
0.2981 
0.6714 
0.5856 
Transforming Growth Factor (TGFß) increases differentiation in vascular smooth muscle 
cells. 
 Results from qPCR of smooth muscle differentiation markers, calponin (CNN1),  α-
smooth muscle actin (SMA), and sm22α (SM22) of cells treated with TGFß, revealed an increase 
in differentiation compared to the control, although one-way Anova did not show a significant 
difference due to a large standard deviation (Figure 4A). Western blotting confirmed a 
qualitative increase in α-smooth muscle actin protein intensity in cells treated with TGFß 
compared to the control (Figure 4B).  
 
Inhibition of Notch by DAPT and addition of TGFß resulted in a smaller increase in vascular 
smooth muscle cell differentiation. 
Cells treated with DAPT and TGFß showed a smaller increase in differentiation in all of 
the smooth muscle cell differentiation markers, although the one way Anova did not reveal a 
significant difference due to a large standard deviation.    There was no significant difference in 
Notch3 gene expression (Figure 4A, 4B). 
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Fiqure 4A. Relative expression of vascular smooth muscle cell differentiation markers: Calponin (CNN1), 
NOTCH3, α-Smooth Muscle Actin (SMA), Smooth muscle myosin heavy chain (SMMHC) and Sm22α (SM22).  
Control denoted as (-/-).  Combined TGFß and DAPT treatment denoted as (+/+).  Significance denoted by asterisks 
(**p-value <0.01) and standard deviation denoted by figure bars. (n=3).  48 hour time course found in supplemental 
data. B. Western blot data for Notch3 and SMA.  Tubulin served as a loading control. 
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Table 2. TGFß 24 hour time course statistics. Significant difference (p-value<0.05) denoted with an asterisk 
 
 
 
 
 
 
 
 
 
 
 
 
Gene treatment 2ΔΔCT Mean 
Difference 
Standard 
Deviation 
P-Value 
CNN1 TGFβ/- 2.403 1.658 >0.05 
CNN1 -/DAPT 0.9368 0.7011 >0.05 
CNN1 +/+ 1.551 1.058 >0.05 
SMA 
SMA 
SMA 
TGFβ/- 
-/DAPT  
+/+ 
0.5974 
0.8974 
0.8641 
0.5974 
0.09572 
0.04786 
0.9946 
0.9887 
0.9875 
Notch3 TGFβ/- 1.487 0.5111 0.2407 
Notch3 -/DAPT 0.5213 0.2999 0.0349 
Notch3 +/+ 0.8953 0.5103 0.8727 
SMMHC TGFβ/- 0.9275 0.7903 0.9975 
SMMHC -/DAPT 1.584 2.107 0.7345 
SMMHC +/+ 0.6034 0.4994 0.5035 
SM22 
SM22 
SM22 
TGFβ/- 
-/DAPT 
+/+ 
6.155 
0.7689 
3.630 
6.77 
0.1999 
3.797 
0.2527 
0.1795 
0.3024 
Discussion 
Results of the study confirmed that Platelet Derived Growth Factor (PDGF) induces 
dedifferentiation in vascular smooth muscle cells (VSMC).  As hypothesized, PDGF reduced 
differentiation in treated cells measured by smooth muscle differentiation genes calponin and α-
smooth muscle actin.   Unexpectedly, smooth muscle differentiation genes, sm22α and smooth 
muscle myosin heavy chain did not reveal a significant decrease in differentiation.  PDGF may 
affect these genes differently than calponin and α-smooth muscle actin.  
The inhibition of Notch signaling by DAPT alone did not produce a substantial difference 
in smooth muscle differentiation.  DAPT is known to be a strong inhibitor of Notch signaling in 
other cell cultures such as endothelial cell cultures.  The data suggests that Notch activity may be 
low in cultured human aortic VSMC. Even with low Notch activity present in the cultured 
VSMC, a significant decrease in smooth muscle actin gene expression was seen in cells treated 
with both PDGF and DAPT, compared to PDGF treated cells, and a greater decrease in gene 
expression compared to the control.  This result indicates that Notch signaling may interact with 
PDGF.  To further reinforce this result, cells treated with both PDGF and DAPT showed a 
significant decrease in Notch3 gene expression compared to the control.  Western blotting also 
showed a decrease in Notch3 and α-smooth muscle actin protein intensity in DAPT treated cells, 
as well as in cells treated with both PDGF and DAPT.   Notch3 and α-smooth muscle actin were 
the only proteins analyzed using western blotting due to the availability of primary antibodies. 
Results of the study also confirmed that Transforming Growth Factor (TGFß) induces 
differentiation in vascular smooth muscle cells (VSMC).  As hypothesized, TGFß increased 
differentiation in treated cells measured by smooth muscle differentiation genes calponin, α-
smooth muscle actin and sm22α.  Unlike the other differentiation markers, smooth muscle 
myosin heavy chain gene expression was not greatly increased; indicating TGFß may interact 
with this gene differently than the others. Due to a large standard deviation, no significant 
difference was found in the TGFß treated cells.   
As in the PDGF experiments, there proved to be low Notch activity in the human aortic 
cultured cells, although there was a significant decrease in Notch3 gene expression in the cells 
treated with DAPT in the TGFß experiments.  This decrease was not maintained during the 48 
hour time course.  Combined TGFß and DAPT treatment resulted in a smaller increase in 
differentiation as hypothesized, although a large standard deviation prevented a significant 
difference to be found.  Results of the TGFß treatment did not reinforce an interaction between 
TGFß and Notch signaling.   
Further studies must be conducted to uncover the relationship between PDGF, TGFß and 
Notch signaling.  A future study may overexpress Notch signaling in VSMC to potentiate the 
relationship between the growth factors and Notch signaling.   In all, results of this study showed 
that PDGF induces dedifferentiation in VSMC and TGFß induces differentiation of VSMC. The 
results also show that these growth factors act in expected ways to regulate smooth muscle 
differentiation genes. Inhibition of Notch signaling by DAPT in the presence or absence of these 
growth factors did not have a substantial effect on their differentiation and dedifferentiation 
capabilities. Although in the combined presence of PDGF and DAPT there was a greater 
decrease in Notch3 and α-smooth muscle actin expression. The data suggest that Notch signaling 
may interact with PDGF signaling to control smooth muscle differentiation.  The relationship 
between PDGF and Notch signaling may lead to drug therapies that prevent atherosclerosis and 
the restenosis process. 
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Supplemental Data: Relative expression of vascular smooth muscle cell differentiation markers: Calponin (CNN1), NOTCH3, 
α-Smooth Muscle Actin (SMA), Smooth muscle myosin heavy chain (SMMHC) and Sm22α (SM22).  Control denoted as (-/-).  
Combined treatment denoted as (+/+).  Significance denoted by asterisks (*p-value<0.05, **p-value <0.01, ***p-value <0.001)   
and standard deviation denoted by figure bars. 
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